HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael J. Smith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rinder, C. S. Articles by Smith, B. R. Search for Related Content PubMed PubMed Citation Articles by Rinder, C. S. Articles by Smith, B. R.

J Thorac Cardiovasc Surg 1999;118:460-466
© 1999 Mosby, Inc.

CARDIOPULMONARY SUPPORT AND PHYSIOLOGY

SELECTIVE BLOCKADE OF MEMBRANE ATTACK COMPLEX FORMATION DURING SIMULATED EXTRACORPOREAL CIRCULATION INHIBITS PLATELET BUT NOT LEUKOCYTE ACTIVATION

Supported by National Institutes of Health grants HL47193 (B. R. Smith) and HL02668 (H. M. Rinder) and by Alexion Pharmaceuticals. C. S. Rinder is a recipient of an American Heart Association Clinician-Scientist Award.

Address for reprints: Christine S. Rinder, MD, Department of Anesthesiology, Tompkins 3, Yale University School of Medicine, 333 Cedar St, PO Box 8051, New Haven, CT 06510-8051 (E-mail christine.rinder{at}yale.edu).

Objective: Complement activation is induced by cardiopulmonary bypass, and previous work found that late complement components (C5a, C5b-9) contribute to neutrophil and platelet activation during bypass. In the present study, we blocked C5b-9 formation during extracorporeal recirculation of whole blood to assess whether the membrane attack complex was responsible for both platelet and leukocyte activation.
Methods: In a simulated extracorporeal model that activates complement (C3a and sC5b-9), platelets (CD62P expression, leukocyte-platelet conjugate formation), and leukocytes (increased CD11b expression and neutrophil elastase), we examined an anti-human C8 monoclonal antibody that inhibits C5b-9 generation for its effects on cellular activation.
Results: Anti-C8 significantly inhibited sC5b-9 formation but did not block C3a generation. Anti-C8 also significantly inhibited the increase in platelet CD62P and monocyte-platelet conjugate formation seen with control circulation. Moreover, compared with control circulation, in which the number of circulating platelets fell by 45%, addition of anti-C8 completely preserved platelet counts. In contrast to blockade of both C5a and sC5b-9 during simulated extracorporeal circulation, neutrophil activation was not inhibited by anti-C8. However, circulating neutrophil and monocyte counts were preserved by addition of anti-C8 to the extracorporeal circuit.
Conclusions: The membrane attack complex, C5b-9, is the major complement determinant of platelet activation during extracorporeal circulation, whereas C5b-9 blockade has little effect on neutrophil activation. These data also suggest a role for platelet activation or C5b-9 (or both) in the loss of monocytes and neutrophils to the extracorporeal circuit.

This article has been cited by other articles:

				J. W. Hammon Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389. [Full Text]

				C. S. Rinder, M. J. Smith, H. M. Rinder, D. N. Cortright, R. M. Brodbeck, J. E. Krause, and B. R. Smith Leukocyte Effects of C5a-Receptor Blockade During Simulated Extracorporeal Circulation Ann. Thorac. Surg., January 1, 2007; 83(1): 146 - 152. [Abstract] [Full Text] [PDF]

				Y. Sato, Y. Hiramatsu, S. Homma, M. Sato, S. Sato, S. Endo, and Y. Sohara Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 346 - 350. [Abstract] [Full Text] [PDF]

				K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941. [Abstract] [Full Text] [PDF]

				P. Menasche and L. H. Edmunds Jr. Extracorporeal Circulation: The Inflammatory Response Card. Surg. Adult, January 1, 2003; 2(2003): 349 - 360. [Full Text]

				D. Paparella, T.M. Yau, and E. Young Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 232 - 244. [Abstract] [Full Text] [PDF]

				G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]

				M. Fung, P. G. Loubser, A. Undar, M. Mueller, C. Sun, W. N. Sun, W. K. Vaughn, and C. D. Fraser Jr Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 113 - 122. [Abstract] [Full Text] [PDF]

				M. G. Barnes and A. A. Weiss BrkA Protein of Bordetella pertussis Inhibits the Classical Pathway of Complement after C1 Deposition Infect. Immun., May 1, 2001; 69(5): 3067 - 3072. [Abstract] [Full Text] [PDF]

				C. F. Mojcik and J. H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2001; 71(2): 745 - 754. [Abstract] [Full Text] [PDF]